Noting the CSL R&D day.

There’s lots of good charts. Below, you can see Hizentra, the subcutaneous IVIG product, continuing to dominate the competitive landscape, which it has done since day 1.

You can see they are very good at coming up with novel therapeutic interventions that address unmet clinical needs.

But what is the point of browsing all that stuff, from a stock picking perspective (as in we think its worthwhile, but what’s the mechanism to a good investment outcome at work here?).

Some of it is handwaving. Quality companies tend to be systematically under-priced, for a range of semi-plausible behavioural explanations, and owning a basket of companies that score well on such a quant model has been shown the generate alpha over long periods of time.

The above graphs suggest quality, as do the below regression methodology.

The handwaving can get fractionally more explicit, in that a strong successful product pipeline can translate into a true earnings trajectory, that is higher than the market expects, and the strong resultant franchise value (e.g. these guys will keep innovating at a higher rate than the market expects) can translate into a true earnings multiple that is higher than the market expected.

So, what is it that one is doing here?

To some extent, it’s due diligence. “I think it’s a quality stock, and all those graphs about success sure seem indicative that they know what they are doing/have good products/can compete effectively”. That big R&D budget as a % of sales is also the sort of thing that can keep a competitive lead intact (indeed, R&D declining is something to watch for).

Sometimes it is validation of the obvious. A company without an R&D day would be a red flag, but if that sounds silly to you than think of the many mining company production presentations that have hit the ASX over time, which have revolved around an unbuilt mine with not a digger in sight a 1000 clicks from any rail to port infrastructure.

So, coming full circle, what’s the point of this note? Well, it’s about trying to work out “what’s the mechanism”. That’s the funds management side of things. The advice side is even more direct, but still often omitted. It’s the evidentiary documentation. Someone, somewhere, has got to actually look at it (this detail, here, the R&D day), and say something that’s both forward looking and objectively aligned. And that’s not easy.

Important Information: This document has been prepared by Aequitas Investment Partners ABN 92 644 165 266 (“Aequitas”, “our”, “we”), a Corporate Authorised Representative (no. 1284389) of C2 Financial Services, (Australian Financial Services Licensee no. 502171), and is for distribution within Australia to wholesale clients and financial advisers only.

This document is based on information available at the time of publishing, information which we believe is correct and any opinions, conclusions or forecasts are reasonably held or made as at the time of its compilation, but no warranty is made as to its accuracy, reliability or completeness. To the extent permitted by law, neither Aequitas nor any of its affiliates accept liability to any person for loss or damage arising from the use of the information herein.

Please note that past performance is not a reliable indicator of future performance.

General Advice Warning: This document has been prepared without taking into account your objectives, financial situation or needs, and therefore you should consider its appropriateness, having regard to your objectives, financial situation and needs. Before making any decision about whether to acquire a financial product, you should obtain and read the relevant Product Disclosure Statement (PDS) or Investor Directed Portfolio Service Guide (IDPS Guide) and consider talking to a financial adviser.

Taxation warning: Any taxation considerations are general and based on present taxation laws and may be subject to change. Aequitas is not a registered tax (financial) adviser under the Tax Agent Services Act 2009 and investors should seek tax advice from a registered tax agent or a registered tax (financial) adviser if they intend to rely on this information to satisfy the liabilities or obligations or claim entitlements that arise, or could arise, under a taxation law.

Receive our investment insights

Something went wrong. Please check your entries and try again.